Darb-Esfahani S[Author] - Search Results

Year	Number of Results
2008	3
2009	10
2010	10
2011	10
2012	10
2013	8
2014	7
2015	10
2016	18
2017	13
2018	14
2019	6
2020	4
2021	1

1

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.

Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt WD, Blohmer JU, Karn T, Pfitzner BM, Kümmel S, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching PA, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Loibl S. Denkert C, et al. Among authors: darb esfahani s. Lancet Oncol. 2018 Jan;19(1):40-50. doi: 10.1016/S1470-2045(17)30904-X. Epub 2017 Dec 7. Lancet Oncol. 2018. PMID: 29233559

2

Checkpoint-inhibition in ovarian cancer: rising star or just a dream?

Pietzner K, Nasser S, Alavi S, Darb-Esfahani S, Passler M, Muallem MZ, Sehouli J. Pietzner K, et al. Among authors: darb esfahani s. J Gynecol Oncol. 2018 Nov;29(6):e93. doi: 10.3802/jgo.2018.29.e93. J Gynecol Oncol. 2018. PMID: 30207101 Free PMC article. Review.

3

Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment.

Hoffmann K, Berger H, Kulbe H, Thillainadarasan S, Mollenkopf HJ, Zemojtel T, Taube E, Darb-Esfahani S, Mangler M, Sehouli J, Chekerov R, Braicu EI, Meyer TF, Kessler M. Hoffmann K, et al. Among authors: darb esfahani s. EMBO J. 2020 Mar 16;39(6):e104013. doi: 10.15252/embj.2019104013. Epub 2020 Feb 3. EMBO J. 2020. PMID: 32009247 Free PMC article.

4

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Törne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G. Denkert C, et al. Among authors: darb esfahani s. J Clin Oncol. 2010 Jan 1;28(1):105-13. doi: 10.1200/JCO.2009.23.7370. Epub 2009 Nov 16. J Clin Oncol. 2010. PMID: 19917869 Clinical Trial.

5

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.

Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, Kümmel S, Hilfrich J, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Darb-Esfahani S, Schmitt WD, Dan Costa S, Gerber B, Engels K, Nekljudova V, Loibl S, von Minckwitz G; German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) Investigators. Untch M, et al. Among authors: darb esfahani s. Lancet Oncol. 2016 Mar;17(3):345-356. doi: 10.1016/S1470-2045(15)00542-2. Epub 2016 Feb 8. Lancet Oncol. 2016. PMID: 26869049 Clinical Trial.

6

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, Schem C, Fisch K, Darb-Esfahani S, Mehta K, Sotiriou C, Wienert S, Klare P, André F, Klauschen F, Blohmer JU, Krappmann K, Schmidt M, Tesch H, Kümmel S, Sinn P, Jackisch C, Dietel M, Reimer T, Untch M, Loibl S. Denkert C, et al. Among authors: darb esfahani s. J Clin Oncol. 2015 Mar 20;33(9):983-91. doi: 10.1200/JCO.2014.58.1967. Epub 2014 Dec 22. J Clin Oncol. 2015. PMID: 25534375 Clinical Trial.

7

Discovery of Prognostic Markers for Early-Stage High-Grade Serous Ovarian Cancer by Maldi-Imaging.

Kulbe H, Klein O, Wu Z, Taube ET, Kassuhn W, Horst D, Darb-Esfahani S, Jank P, Abobaker S, Ringel F, du Bois A, Heitz F, Sehouli J, Braicu EI. Kulbe H, et al. Among authors: darb esfahani s. Cancers (Basel). 2020 Jul 22;12(8):2000. doi: 10.3390/cancers12082000. Cancers (Basel). 2020. PMID: 32707805 Free PMC article.

8

Discovery and Validation of Novel Biomarkers for Detection of Epithelial Ovarian Cancer.

Kulbe H, Otto R, Darb-Esfahani S, Lammert H, Abobaker S, Welsch G, Chekerov R, Schäfer R, Dragun D, Hummel M, Leser U, Sehouli J, Braicu EI. Kulbe H, et al. Among authors: darb esfahani s. Cells. 2019 Jul 12;8(7):713. doi: 10.3390/cells8070713. Cells. 2019. PMID: 31336942 Free PMC article.

9

EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM.

Naskou J, Beiter Y, van Rensburg R, Honisch E, Rudelius M, Schlensog M, Gottstein J, Walter L, Braicu EI, Sehouli J, Darb-Esfahani S, Staebler A, Hartkopf AD, Brucker S, Wallwiener D, Beyer I, Niederacher D, Fehm T, Templin MF, Neubauer H. Naskou J, et al. Among authors: darb esfahani s. Mol Cancer Res. 2020 Feb;18(2):278-286. doi: 10.1158/1541-7786.MCR-19-0141. Epub 2019 Nov 8. Mol Cancer Res. 2020. PMID: 31704732

10

Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium.

Guan J, Darb-Esfahani S, Richter R, Taube ET, Ruscito I, Mahner S, Woelber L, Prieske K, Concin N, Vergote I, Van Nieuwenhuysen E, Achimas-Cadariu P, Glajzer J, Woopen H, Stanske M, Kulbe H, Denkert C, Sehouli J, Braicu EI. Guan J, et al. Among authors: darb esfahani s. J Cancer Res Clin Oncol. 2019 Apr;145(4):1063-1073. doi: 10.1007/s00432-019-02877-4. Epub 2019 Feb 27. J Cancer Res Clin Oncol. 2019. PMID: 30810838

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results